Loading...
NYSE: BDX
Becton, Dickinson and Company
Healthcare · Medical - Instruments & Supplies
●S&P 500 since 1972
Market Cap
$57.05B
52w High
$187.35
52w Low
$127.59
P/E
25.55
Volume
715.45K
Outstanding Shares
362.30M
Valuation Data Insufficient
The DCF model's fair value estimate is more than 3× the current stock price. This typically indicates unreliable model inputs — such as irregular cash flows or balance sheet distortions — rather than a genuine opportunity, so the valuation is not shown.
Company profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
CEOThomas E. Polen Jr.
SectorHealthcare
IndustryMedical - Instruments & Supplies
Employees70,000
IPO dateFeb 21, 1973
Valuation
Forward P/E—
EV/EBITDA10.39
Enterprise value$51.49B
Stock splits
Feb 10, 2026159:125
Apr 1, 202241:40
Aug 21, 19982:1
Aug 16, 19962:1
Mar 1, 19932:1
Mar 3, 19862:1
Profitability & growth
Revenue growth1.63%
Gross margin45.76%▲0.48%vs FY2024
Operating margin12.4%▼0.63%vs FY2024
ROE6.61%▲0.35%vs FY2024
Analyst consensus
RatingBuy
Target price$193.80▲23.08%
16
Buy
16
Hold
1
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
View
EPS
Actual vs estimate by quarter
Q3FY25
ActualEst.
$3.68
$3.40
Q4FY25
ActualEst.
$3.96
$3.92
Q1FY26
ActualEst.
$2.91
$2.21
Q2FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q3FY25
ActualEst.
$5.51B
$5.49B
Q4FY25
ActualEst.
$5.89B
$5.91B
Q1FY26
ActualEst.
$5.25B
$5.15B
Q2FY26
Next Est.
—